- Home
- Equipment
- north america
- antigen receptors
Show results for
Refine by
Antigen Receptors Equipment Supplied In North America
29 equipment items found
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-CAR candidates are being developed as allogeneic, off-the-shelf approaches through gene modification of human placental hematopoietic stem cell-derived natural killer (NK) cells. Various CAR constructs against hematological and solid tumor targets are under pre-clinical ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
Chimeric Antigen Receptor (CAR) NK Cells: Alphageneron is developing ‘off-the- shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based cancer therapeutics that target tumors expressing mHsp70, and other (undisclosed) targets. ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Licensed from the National Institutes of Health, VCAR33 is a CD33-directed chimeric antigen receptor T cell (CAR-T) therapy. A T cell therapy using the same CAR construct as VCAR33 is being studied in a multi-site Phase 1/2 clinical trial as an autologous monotherapy bridge-to-transplant for relapsed and/or refractory AML patients, sponsored by the National ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-221 is a preclinical short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of B-cell malignancies. CYAD-221 is engineered to co-express a CD19 chimeric antigen receptor and an shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor derived) CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed by a broad range of tumor cells and the novel inhibitory ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor cells, and (ii) short hairpin RNA (shRNA) technology ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC50 of ~5 μM. Anti-inflammatory ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
Best in class MHC Class II Monomers: ProM2® Class II MHC Monomers are pre-biotinylated and can be readily adapted either to detect and separate single-antigen specific T cells or implement specialist solid or solution phase immunoassays for measuring interactions of predefined MHC Class II-peptide complexes with ligands such as monoclonal antibodies, recombinant T cell ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T cell to recognize a specific protein that is present on the surface of other cells, including cancer cells. Upon recognition of the target cell via the ...
Manufactured by:ACROBiosystems based inNewark, DELAWARE (USA)
Name:B-cell maturation protein. Target Synonym:B-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
ProM1™ MHC Class I Monomers, biotin labeled enabling specialist assays for defined MHC Class I peptide target ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
Epitope is a part of an antigenic protein consisting of a sequence of 8 to 15 amino acids that provide the immunogenicity of an antigen protein. Immune receptors such as TCR, BCR, and MHC of various immune cells including T cells, B cells, and macrophages recognize epitopes and lead to various immune responses. As a simple example, when a ...
![GeneTex - Model CD19 -[HIB19] (PE-Cy7) - Antibody](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzExMzU1Ny9pbWFnZXMvMTEzNTU3XzBfMjAyMDEwMjkwNjExMzA2NzI0ODA1XzQwMC5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MjQwLCJoZWlnaHQiOjE0NX19fQ== "GeneTex - Model CD19 -[HIB19] (PE-Cy7) - Antibody")
Manufactured by:GeneTex, Inc. based inIrvine, CALIFORNIA (USA)
The HIB19 antibody reacts with human CD19, a 95 kDa glycoprotein which acts as a co-receptor, along with CD21, CD81 and CD225, in support of the functional B cell receptor (BCR). This complex provides antigen-specific recognition and subsequent activation of B cells to proliferate and differentiate into antibody-secreting cells (plasma cells) or ...
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells, potentially leading to more robust anti-tumor ...
Manufactured by:ANP Technologies, Inc. based inNewark, DELAWARE (USA)
Many bioanalytical methods to detect analytes in these fluids are based on the interaction of a binding pair, such as an antibody and its antigen or a receptor and its ligand. An interfering protein is any protein that blocks the specific interaction of the binding pair, causing false negative or false positive ...